Login
Navigate Fool.com
Will ISPH beat
the market?
Community Rating: 3 Stars: Appealing

0.00 0.00 (0.00%)

Quote as of

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open 0.00
Previous Close 0.00
Daily Range 0.00 - 0.00
52-Week Range 0.00 - 0.00
Market Cap 0.0000
P/E Ratio 0.00
Dividend (Yield) 0.00 (0.0%)
Volume 0
Average Daily Volume 0
Current FY EPS -0.31

How do you think ISPH
will perform against the market?

Top ISPH Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

Inspire's Pink Eye Drug AzaSite Draws Generic Challenge

This sought-after drug could soon be facing generic competition.

Merck Gets Warm Tender Reception In $430 Million Inspire Purchase

Merck Inspired to Eye Growth

A bolt-on acquisition of eye-care specialist Inspire.

Closing Bell: The Directionless Day (AAPL, ANF, BA, FXI, ISPH, MRK, NSM, TXN)

Analyst Calls: BRCD, CREE, DUK, HRL, MOLX, RTN, SPWRA, VCLK, WTW ...

Is Alcon a Sell?

We're seeking danger signs among Fools' most beloved stocks.

Why Did My Stock Just Die?

These stocks just rolled over. Can they come back?

Clinical Trial Results Fail to Inspire

Inspire Pharma gets cut in half after a cystic fibrosis trial failure.

Inspire Pharmaceuticals Shares Plunged: What You Need to Know

Is this meaningful? Or just another movement?

Inspire Reveals Weak Trial Results for Cystic Fibrosis Drug

See More ISPH News...

Sector

Healthcare

Industry

Pharmaceuticals

Inspire Pharmaceuticals, Inc. (ISPH) Description

A biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with commercial potential or unmet medical needs. Website:

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks